Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Work In Process (2021 - 2025)

Historic Work In Process for Burning Rock Biotech (BNR) over the last 5 years, with Q4 2024 value amounting to $10.4 million.

  • Burning Rock Biotech's Work In Process fell 968.3% to $10.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $10.4 million, marking a year-over-year decrease of 968.3%. This contributed to the annual value of $10.4 million for FY2024, which is 968.3% down from last year.
  • Burning Rock Biotech's Work In Process amounted to $10.4 million in Q4 2024, which was down 968.3% from $11.5 million recorded in Q4 2023.
  • Burning Rock Biotech's Work In Process' 5-year high stood at $42.4 million during Q4 2021, with a 5-year trough of $2.6 million in Q2 2020.
  • Its 5-year average for Work In Process is $9.6 million, with a median of $5.8 million in 2021.
  • As far as peak fluctuations go, Burning Rock Biotech's Work In Process surged by 112765.71% in 2021, and later tumbled by 7348.49% in 2022.
  • Burning Rock Biotech's Work In Process (Quarter) stood at $3.5 million in 2020, then skyrocketed by 1127.66% to $42.4 million in 2021, then tumbled by 73.48% to $11.2 million in 2022, then rose by 2.17% to $11.5 million in 2023, then dropped by 9.68% to $10.4 million in 2024.
  • Its Work In Process was $10.4 million in Q4 2024, compared to $11.5 million in Q4 2023 and $11.2 million in Q4 2022.